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Background: Local slow release implant provided long term and stable drug release
in the lesion. The objective of this study was to fabricate biodegradable slow release
INH/PLLA tablet via 3 dimensional printing technique (3DP) and to compare the
drug release characteristics of three different structured tablets in vitro.
Methods: Three different drug delivery systems (columnar-shaped tablet (CST),
doughnut-shaped tablet (DST) and multilayer doughnut-shaped tablet (MDST)) were
manufactured by the three dimensional printing machine and isoniazid was loaded
into the implant. Dynamic soaking method was used to study the drug release
characteristics of the three implants. MTT cytotoxicity test and direct contact test
were utilized to study the biocompatibility of the implant. The microstructures of the
implants’ surfaces were observed with electron microscope.
Results: The PLLA powder in the tablet could be excellently combined through 3DP
without disintegration. Electron microscope observations showed that INH
distributed evenly on the surface of the tablet in a “nest-shaped” way, while the
surface of the barrier layer in the multilayer doughnut shaped tablet was compact
and did not contain INH. The concentration of INH in all of the three tablets were
still higher than the effective bacteriostasis concentration (Isoniazid: 0.025 ~ 0.05 μg/
ml) after 30 day’s release in vitro. All of the tablets showed initial burst release of the
INH in the early period. Drug concentration of MDST became stable and had little
fluctuation starting from the 6th day of the release. Drug concentration of DST and
CST decreased gradually and the rate of decrease in concentration was faster in DST
than CST. MTT cytotoxicity test and direct contact test indicated that the INH-PLLA
tablet had low cytotoxicity and favorable biocompatibility.
Conclusions: Three dimensional printing technique was a reliable technique to
fabricate complicated implants. Drug release pattern in MDST was the most stable
among the three implants. It was an ideal drug delivery system for the antibiotics.
Biocompatibility tests demonstrated that the INH-PLLA implant did not have
cytotoxicity. The multilayer donut-shaped tablet provided a new constant slow
release method after an initial burst for the topical application of the antibiotic.
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Local slow release implant provided long term and stable drug release in the lesion. In
contrast to oral drug administration, it increased the topical drug concentration while
the blood drug concentration was maintained at a relatively low level. In this way, local
drug delivery enhanced the drug therapeutic efficacy and decreased systemic side ef-
fects. Recent local drug delivery systems were mainly used for treating tumor and
chronic infectious diseases [1,2]. In order to manufacture drug delivery devices that
could release drug smoothly, and for the drug release rate to reach or close to zero
order, researchers studied various drug loading devices, including doughnut shaped tab-
lets, multilayer tablets and microparticles etc. [3-5].
Doughnut shaped tablets maintained the stability of drug release rate through keep-
ing the effective drug release surface of the device constant. Traditionally, such devices
were produced through compressing the mixture of drug and the drug loading matrix.
However, the uniformity of the mixture was limited. Detachment between the different
layers of the multilayer tablet processed by compression was likely to happen. Those
disadvantages directly influenced the drug release pattern.
The application of three dimensional printing (3DP) technique had received wide at-
tention [6-8], since the technique was first introduced by Sachs etc. 3DP machine fabri-
cated 3D structure models designed by computer, through binding powders layer by
layer with binding liquid. It had great advantages in processing drug loading implants
with complicated internal structures [9-11]. Model drugs could be dissolved in binding
liquid evenly and injected on the powder layer by the printing head very precisely. The
effective therapeutic concentration of the model drug should be low, due to the limita-
tion of drug loading ability of the implant. INH as a classic antituberculosis agent with
minimal inhibitory concentration between 0.025 ~ 0.05 μg/ml was an ideal model drug.
In this study we manufactured an INH-PLLA implant via 3DP technique, compared
the release feature of different structures of implants in vitro, and studied the biocom-
patibility of the INH-PLLA implants created via 3DP technique.Methods
Material and equipment
PLLA, Mw = 100 KD, was provided by Dikan Biomedical Co., Ltd (Chengdu, China).
Isoniazide was purchased from TianRui Pharmaceutical Co., Ltd (Zhejiang, China).
Acetone and alcohol were obtained from Shi Yi Chemical Reagent Limited Company
(Shanghai, China). 3 DP machine was designed and built by Fochif Mechatronics
Technique Co. Ltd (Shanghai, China).Preparation of binding liquid and PLLA powder
Binding liquid was the mixture of acetone, alcohol and DI water at the ratio of 20:4:5
(v/v). Moreover, it also contained some accessory ingredients, including glycerol, poly-
vinylpyrrolidone and lauryl sodium sulfate. INH bulk drug was dissolved in the binding
liquid at a concentration of 120 mg/ml. INH containing and absent binding liquid were
filled into ink boxes respectively. Ground PLLA powder with a diameter between
50-75 um was selected after processing by a grinder. All the drugs and powders were
stored in a P2O5 vacuum dryer.
Figure 1 INH-PLLA implant ideograph.
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In this research study we designed three implants with different structures, as shown in
Figure 1. The structures were columnar-shaped tablet (CST), doughnut-shaped tablet
(DST) and multilayer doughnut-shaped tabled (MDST), with an outer diameter of
9 mm. Their heights were 5 mm, 5 mm, 7 mm respectively. Both DST and MDST had
a hole in the center with a diameter of 3 mm. MDST had barrier layers at the top and
bottom extremities of the implant with a thickness of 1 mm each. The volume and the
surface area of the implant was shown in Table 1.Fabrication of the implant
The printing parameter was shown in Table 2. The machine was reset and covered with
a layer of PLLA powder on the surface of the working platform. The printing machine
would smooth the powder automatically with the roller, and then binding liquid would
be injected on the surface of the PLLA powder layer to form a certain pattern accord-
ing to the printing parameters. To combine the powder particles more firmly, injection
of the binding liquid would be repeated as necessary. The working platform descended
a certain height in the direction of z-axis when the combination of a single layer was
finished. Another PLLA powder layer could be laid with the same thickness, and then
the machine injected binding liquid at the same place as the previous layer. Thus the
two PLLA powder layers combined together. Repeating those processes, the machine
could fabricate certain shapes of PLLA implant according to the model programmed in
the computer (Figure 2).
After the printing process, the drug implants were kept inside the PLLA powder
to dry for 30 min under room temperature. Additional PLLA powder was removed
and the implants were stored in the P2O5 vacuum dryer. The PLLA powder on the
surface was removed 12 hours later. To combine the powder particles more firmly,
a few coats of binding liquid was sprinkled on the surface of the implant evenly.Table 1 Common feature of the implants




Table 2 Printing parameter of the INH-PLLA implant with different structures
Pattern Layer thickness/μm Layer Printing time Binding liquid
CST 200 1st-25th 15 INH-binding liquid
DST 200 1st-25th 15 INH-binding liquid
MDST 200 1st-5th & 31st-35th 15 Empty-binding liquid
200 6th-30th 15 INH-binding liquid
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was moistened by acetone 7 days after the printing. All the products were dried
for 12 days in the vacuum dryer.Biocompatibility detection
Separation and cultivation of the rat mesenchymal stem cell
SD rats of either gender were decapitated and soaked in 70% alcohol for 10 min; the
femur and tibia of both posterior legs of the rats were separated under aseptic tech-
nique and the soft tissue was removed with PBS solution; the bone was cut and the
bone marrow was washed into the 10 ml aseptic centrifuge tube with 10 ml medium
containing 10% FBS. The cell suspension was collected into 15 ml centrifuge tube and
divided into two equal shares. The cell suspension was centrifuged for 15 min at the
speed of 1000 rpm/min under room temperature. The supernatant was abandoned and
5 ml culture medium was added to suspend the cells again. The cell suspension was in-
oculated into 6-well plates and cultured at 37°C, 5% CO2 thermostat. Half of the cul-
ture medium was replaced 24 hours after the inoculation, and the fluid was thereafter
changed every 3 days. The cells were sub-cultured after 80-90% confluence.
Preparation of leaching liquor
100 mg of the INH-PLLA implant was lixiviated in 500 ml fetal bovine serum at 37°C
attemperator for 3 days. Filter liquor was sterilized by filtrating through 0.22 um micro-
pore film. The filter liquor was stored in the refrigerator at 4°C.Figure 2 Schematic diagram of the 3D printing. A: Lateral view of the printing machine; The roller
smooth the powder when it’s moving; B: Lateral view of the printing machine; The printing head inject the
binding liquid on the suface of the powder layer; C: Anterior view of the printing machine; Several round
circle patterns are printed on the PLLA powder layer.
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Rat mesenchymal stem cell were digested by 0.25% trypsin to prepare cell suspension.
The cell density was modulated to 2 × 104/ml. 200 μl cell suspension was seeded into
each well of 96-well culture plate and cultured in incubator at 37°C with 5% CO2 for
24 h to make the cells attached. 15 wells were set as experimental group and another
15 wells as control group. The original culture medium in each group was altered with
200 μl leaching liquor and normal DMEM culture medium respectively. The cells were
cultured in the incubator at 37°C with 5% CO2. 5 wells of each group were selected
after being cultured for 24 h, 48 h and 72 h. Then 20 μl MTT (5 mg/ml) was added
and incubated for 4 h at 37°C. The supernatant was removed and DMSO 150 μl was
added, and shaken for 10 min. The OD value was measured at immune microplate
reader under 490 nm wavelenth. The relative growth rate (RGR) was caculated on the
basis of the mean OD value of each timing. RGR% = 100 ×ODsample/ODcontrol.
Direct contact test
The implants were sterilized with ethylene oxide and cut into small pieces with a size
of about 2 × 2 × 2 mm. The rat mesenchymal stem cell suspension was kept agitated.
2 ml cell suspension was imbibedand seeded in the wells of 6-well culture plate. 3 wells
were set as experimental group and the other 3 as control group. The small pieces of
INH-PLLA implant were placed into the experimental group and kept the implant un-
disturbed. The cells were cultured in the incubator at 37°C with 5% CO2. After 1, 2 and
3 days, the inverted phase contrast microscope was used to observe the cell morph-
ology and proliferation.In vitro drug release experiment
Soaking method was used in the in vitro release experiment. Deionized water was the
release medium. 10 ml deionized water was filled into a glass bottle. The implant was
tied up with a fine line and hung in the release medium. The glass bottle was kept in
the constant temperature vibrator which vibrating rate was 100 times/min at 37°C.
10 ml solution was taken out every other day and stored under frozen condition, and
then the bottle was filled with 10 ml fresh deionized water. The release experiment
lasted 30 days.
The sample was tested with RT-HPLC. The ODS-SP (4.6 × 250 × 5u) was used as
chromatographic column. The flowing phase was methanol-DSP (0.02 mol/L, the pH
was adjusted to 4.5 with phosphoricacid) (75:25, V/V). The UV wave length was
254 nm and the flowing rate was 1 ml/min.Data statistical analysis
The experimental data was analyzed with SPSS13.0 software, and the result was
expressed as X  S . T-test was used for comparision between groups of MTT and P <
0.05 was statistically significant.Results
Appearance of the INH-PLLA implant
The PLLA implant is shown in Figure 3. The combination of the PLLA powder was
quite compact and there was no separation between layers. The size of the implant
Figure 3 Appearance of the implant. A: Anterior view of the semi-finished implant; B: Anterior view of
the finished implant; C: Lateral view of the semi-finished implant; D: Lateral view of the finished implant.
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surface of the semi-finished implant, and the particles may fall off from the surface of
the implant. After the post printing processing, the particles bonded more closely and
no additional powder fell off. The holes in the implant surface also reduced in size.Microstructure of the INH-PLLA implant
The PLLA implant was observed under microscope and the result was shown in
Figure 4. After post printing processing, the surface of the barrier layer was compact
and only a few holes could be found. No INH could be observed on the barrier layer.
There were many micropores with diameters around 50-100 um which were uniformlyFigure 4 Observation of the implant under microscope. A: Microstructure of barrier layer (500×);
B: Microstructure of the drug release area; the white arrows shows the INH (300×); C: Microstructure of the
tablet after 30 days of drug release (400×).
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embeded into the PLLA and distributed in nested way.
After 30 days of drug release, the INH in the drug release system was dissolved into
the medium and many micropores were left on the surface of the implant. The pore
size was larger than before.Result of the direct contact test
INH-PLLA implant and rat mesenchymal stem cells were co-incubated for 3 days. The
cells grew well and attached. The number of cells increased from the first day to the third
as shown in Figure 5. No abnormal or metamorphic cells were found around the implant,
no reaction zone was discovered and the cells grew near the implant. There were no obvi-
ous differences beween the experimental groups and control groups in cell morphology,
number and distribution. The cytotoxicity graded 0.MTT cytotoxicity test
The result of the cytotoxicity test is shown in Table 3. OD values between the experimen-
tal and control groups at 3 time points showed no significant difference. The RGR% in
24 h, 48 h and 72 h was 103%, 96% and 96%, respectively.Result of the in vitro drug release experiment
All of the three drug delivery systems showed initial burst release. The INH concentration
of the MDST, DST and CST was 23.52 ± 2.49 μg/ml, 37.86 ± 3.28 μg/ml and 31.47 ±
3.51 μg/ml respectively, after two days of release. The concentration of INH decreased
gradually as shown in Figure 6. The amount of the drug released from MDST became
stable and fluctuated slightly from the 6th day onwards. The drug release rate of DST
and CST both decreased gradually,but the rate of release in DST decreased faster com-
pared to CST.Discussion
The rapid prototyping technique originated from the United States in the 1980s. The
major characteristic of this technique was in the method of manufacture. Materials
were piled up and combined layer by layer under the control of a computer, whichFigure 5 Cells grew around the tablet. A: The cellular morphology after 24 hours of incubation; B: The
cellular morphology after 72 hours of incubation.
Table 3 MTT data of the PLLA implant and the statistical analysis results
Group OD Value
24 h 48 h 72 h
Experimental group (n = 5) 0.696 ± 0.022 0.678 ± 0.035 0.680 ± 0.028
Control group (n = 5) 0.675 ± 0.031 0.701 ± 0.029 0.711 ± 0.023
t 1.24 1.13 1.91
P >0.05 >0.05 >0.05
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Many types of rapid prototyping techniques had been developed ever since. 3DP tech-
nique attracted a lot of attention since it was proposed by Sachs etc. It could manufac-
ture products with complex shapes and intricate internal structures. It also attracted
extensive attention in relation to its application in the medical field. Tissue engineering
scaffolds with unique structure could be prepared with the use of 3DP machines [12].
It also could make bone fracture models with 3D CT data for the doctor’s reference be-
fore operation, and also make individualized implants to fix bone deficits [13].
Three dimensional printing technique consisted of two major elements, which were
binding liquid and matrix. The binding liquid and matrix were selected according to
the requirement of the experiment. In this study, we used biodegradable PLLA as the
matrix and the organic solvent with INH as the binding liquid [10,14]. The experimen-
tal results showed that slow release implants were obtained using the above materials
which had excellent binding structures without disintegration. After post printing pro-
cessing, slow release implant regained fine appearance and hardness without dropping
any powders from the surface of the implant. PLLA was an ideal material to prepare
biodegradable slow release implant. Observing the microstructure of the implant, we
could find that the PLLA powder fused excellently after resolidification and packagedFigure 6 INH released from the INH-PLLA implant fabricated by 3D printing technique in vitro. Data
shown as mean ± S.D., n = 5.
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crystallization could be found. The barrier layer blocked the INH release of MDST.
Local antibiotic drug delivery devices such as drug loading bone cement, bone screw
and bone cement bradde chain played an important role in the prevention and treat-
ment of bone infection [15-18]. The main point of those studies was to fabricate drug
delivery devices that could release drugs steadily for long time in vivo. The drug release
rate was related to its water solubility. Drug with higher water solubility was much eas-
ier to dissolve through the surface of the drug delivery device [19]. The INH used in
this study had high water solubility. It dissolved gradually from the micropores on the
surface of PLLA implant for 30 days. At the end of the experiment, the INH in the mi-
cropores of PLLA had disappeared, when observed under microscope.
In addition, the structure of the implant influenced the drug release pattern. In the
CST, the drug release area decreased as the volume of the implant shrunk. While in
the DST, the release area in the center of the implant enlarged after corrosion. This
partially compensated for the loss in area of the outer surface. When comparing the
drug release pattern of three different shaped implants, we could find that all three
shapes of implant showed initial burst release, which may be related to the surface dif-
fusion mechanism [20]. However, the drug release rate became stable after 4 days. A
more stable drug release pattern could be found in MDST compared to the other two
implants. The possible mechanism was that the porosity of the implant influenced the
INH release. There were many micropores distributed in nest shaped way in the outer
and inner surface of the MDST. The INH was mainly released from the micropore of
the drug release area. No micropores could be observed on the barrier layers which
blocked the release of INH. In the MDST structure, the release area could be well
compensated due to the effect of the barrier layers after the center of the implant en-
larged and maintained a constant surface area for drug release. However, there was no
such complementary effect in CST and the drug release area decreased as the experi-
ment progressed, which resulted in the decrease of the drug release rate. DST, which
had the largest initial drug release surface area, showed the fastest initial drug release
rate, and the drug release rate also descended at a faster rate as compared to the other
two tablets.
The drug loading ability was restricted by the total volume of the implant. Thus the
best loading drug should be effective in low concentrations with small total drug
amount in need. INH was an ideal drug for local drug delivery with a minimal effective
concentration of INH of 0.025 ~ 0.05 μg/ml. In the present research, the INH concen-
tration of the three implants was higher than the effective bacteriostasis concentration
within 30 days. The MDST tablet had the highest concentration with 30 days, as the
drug release rate in MDST was relatively slow when compared to the other two tablets.
This finding suggested that the MDST was a useful delivery vehicle, which could con-
trol the release of drug over a prolonged period of time while keeping the concentra-
tion of the drug relatively stable.
Clinical application of biomaterial should meet certain biological evaluation criterion.
ISO10993 which was issued by the international organization for standardization was
the most authoritative and widely used evaluation criterion. In this study, we conducted
the in vitro cytotoxicity test to analyze the biocompatibility of the INH-PLLA implant.
The results of direct contact test demonstrated that the INH-PLLA implant could
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the cell and the implant, cells grew well and distributed evenly around the implant, and
the cytotoxicity still graded 0 after 3 days of co-incubation. The MTT cytotoxicity test
showed that the OD value of the experimental group and the control group did not
have a significant difference. RGR% in all groups was over 96%, which was higher than
70% as required by the ISO10993. The outcome mentioned above initially demon-
strated that the implant did not have any obvious cytotoxicity.
Embolic arteritis commonly occurs around the focus of bone and joint tuberculosis.
Poor or no blood supply in the focus resulted in the inability of the antitubercular agent
to reach the focus after systemic drug delivery. While in using local antitubercular
agent delivery, drugs were directly affected on the focus and high local drug concentra-
tion could be obtained with low total dosage and less systemic side effects. Drug release
pattern of MDST could be divided into two phases which were the initial burst release
and the later stable release. In the burst release phase, high dosage of INH could kill
the mycobacterium tuberculosis in the focus post-operation, and the stable release
phase which lasted over 30 days guaranteed the sustained bacteriostasis and consoli-
dated curative effectiveness. This would provide a new method for the topical drug de-
livery of antituberculosis agentConclusions
3DP was a reliable technique to fabricate complicated implants. The drug was evenly
distributed in the implant. Among the three different structures of tablets, MDST
showed the most stable drug release and therefore was an ideal drug delivery system
for the antibiotic implant. The INH-PLLA implant met the biocompatibility require-
ments. The drug concentration released from the implant was still higher than the min-
imal effective concentration, even after 30 days of drug release. The multilayer donut-
shaped tablet provided a new method of stable release for the topical application of the
antibiotic.
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